To include your compound in the COVID-19 Resource Center, submit it here.

Iressa (ZD1839): Began Phase III trial enrollment

AstraZeneca plc (AZN), London, U.K.
Product: Iressa ( ZD1839)

Read the full 98 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE